Skip to content

In Vitro Maturation as part of the treatment of infertility in women with PolyCystic Ovaries. Is priming with hCG favourable? A prospective randomized study

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ISRCTN
Registry ID
ISRCTN17078060
Enrollment
200
Registered
2007-05-15
Start date
2006-04-01
Completion date
Unknown
Last updated
2015-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Infertility and PCO. Pregnancy and Childbirth Infertility and polycystic ovaries

Interventions

hCG-injection vs no injection 36 hours before aspiration of oocytes. Randomization is performed by a nurse two days before aspiration of immature oocytes. Block randomization is used, at a size of 50

Sponsors

Odense University Hospital (Denmark)
Lead Sponsor

Eligibility

Sex/Gender
Female

Inclusion criteria

Inclusion criteria: 1. Women with PolyCystic Ovaries (PCO) according to Rotterdam criteria (2003) 2. Referred to the Fertility Clinic, Odense University Hospital 3. Candidates for IVF-treatment according to the standards of the Fertility Clinic

Exclusion criteria

Exclusion criteria: 1. Normal ovarial morphology 2. Manifest diseases requiring medication e.g. diabetes mellitus 3. Endocrine diseases, e.g. hyperprolactinaemia, hyper-and hypothyroidism 4. Abuse of drugs or alcohol 5. More than two previous IVF treatments

Design outcomes

Primary

MeasureTime frame
Primary outcome measures amended as of 26/06/2007: 1. Maturation rate (number of mature [M2] oocytes per number of aspirated oocytes) at 30 and 46 hours 2. Fertilization rate (number of fertilized oocytes per number of matured oocytes) at 46 and 70 hours Primary outcome measures provided at time of registration: 1. Maturation rate (number of mature [M2] oocytes per number of aspirated oocytes) 2. Fertilization rate (number of fertilized oocytes per number of matured oocytes)

Secondary

MeasureTime frame
Secondary outcome measures amended as of 26/06/2007: 1. Number of transferable embryos with normal development on day 2 after fertilization, as a fraction of aspirated, matured and fertilized oocytes in IVF and Intra Cytoplasmatic Sperm Injection (ICSI) groups 2. Maturation rate in relation to follicle size (46 hours after maturation) 3. Maturation rate in relation to serum concentrations of various hormones, measured on various cycle days and days of randomization and aspiration Secondary outcome measures provided at time of registration: 1. Number of transferable embryos with normal development on day 2 after fertilization, as a fraction of aspirated, matured and fertilized oocytes in IVF and Intra Cytoplasmatic Sperm Injection (ICSI) groups 2. Maturation rate in relation to follicle size 3. Maturation rate in relation to serum concentrations of various hormones, measured on various cycle days and days of randomization and aspiration

Countries

Denmark

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026